OC06.07: Cost‐effectiveness of the prenatal screening algorithm for the detection of trisomies in patients with intermediate risk

To estimate the cost-effectiveness of prenatal screening algorithm for the detection of trisomies in the context of a middle-income country. Cost-effectiveness study from a health system perspective between 2022-2023. The study population included patients with first trimester screening, adjusted intermediate risk for trisomy 21 (probability 100:1000), and singleton pregnancy in 2 obstetric ultrasound units in Bogotá-Colombia. An analytical decision model was designed to evaluate the outcomes derived from the algorithm recommended by the Fetal Medicine. In Colombia, social security covers the cost of invasive tests but non-invasive tests must be paid for privately. 1899 patients were evaluated and 79 (4%) met the inclusion criteria. The average maternal age was 33.4 ± 5.2 years and gestational age was 12.5 ± 0.5 weeks. 39% (31/79) patients did not have additional tests, 34% (27/79) underwent invasive diagnosis, 22% (17/79) underwent non-invasive tests, and 5% (4/79) were excluded from the analysis due to pregnancy termination. Invasive diagnosis is less expensive (cost reduction $485 USD) and more effective, compared to non-invasive test with a positive result and after, a confirmatory invasive diagnostic test. Our analysis suggests that the prenatal screening algorithm for the detection of trisomies, based on non-invasive tests requiring diagnostic confirmation by invasive tests, is the dominant alternative (less cost-effective) compared to the invasive approach funded by the general health system. Therefore, it is necessary to determine its cost-effectiveness in more robust studies to test this hypothesis. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.